Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in Tennessee
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in Tennessee
| Provider | Medicare | Services |
|---|---|---|
| Associated Pathologists Llc | $42.78 | 19 |
Tennessee Pricing in Context
In Tennessee, CPT code 81332 (Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants) carries an average Medicare payment of $42.78 — 0% above the national benchmark of $42.72. 2 providers across the state submitted claims for this procedure in 2023, performing 20 total services. Individual payments in TN ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in Tennessee is $130.79, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Tennessee sits above the national Medicare average, commercial rates in the state may also run higher than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Tennessee lands near $91.98, with self-pay cash prices typically around $68.05. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants cost in Tennessee?
The average Medicare payment for Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in Tennessee is $42.78, which is 0% above the national average of $42.72. Providers in TN typically bill $130.79 for this procedure.
What does Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants cost with insurance in Tennessee?
With commercial insurance in Tennessee, Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants costs an estimated $91.98. Without insurance, the estimated cash price is $68.05. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in Tennessee?
2 providers in Tennessee billed Medicare for Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in 2023, performing 20 total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants cheaper in Tennessee than the national average?
No — Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants costs 0% above the national average in Tennessee. The state average Medicare payment is $42.78 compared to $42.72 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.